Receptor Mechanisms Mediating the Anti-Neuroinflammatory Effects of Endocannabinoid System Modulation in a Rat Model of Migraine

European Jnl of Neuroscience – Applications sur Google Play

“Calcitonin gene-related peptide (CGRP), substance-P and dural mast cells are main contributors in neurogenic inflammation underlying migraine pathophysiology.

Modulation of endocannabinoid system attenuates migraine pain, but its mechanisms of action remains unclear.

We investigated receptor mechanisms mediating anti-neuroinflammatory effects of endocannabinoid system modulation in in-vivo migraine model and ex-vivo hemiskull preparations in rats.

Selective ligands targeting CB1 and CB2 receptors may provide novel and effective treatment strategies against migraine.”

https://pubmed.ncbi.nlm.nih.gov/32639078/

https://onlinelibrary.wiley.com/doi/abs/10.1111/ejn.14897

Recent Cannabis Use in HIV Is Associated With Reduced Inflammatory Markers in CSF and Blood

 Home“Objective: To determine whether cannabis may reduce HIV-related persistent inflammation, we evaluated the relationship of cannabis use in people with HIV (PWH) to inflammatory cytokines in CSF and blood plasma.

Conclusions: Recent cannabis use was associated with lower levels of inflammatory biomarkers, both in CSF and blood, but in different patterns. These results are consistent with compartmentalization of immune effects of cannabis. The principal active components of cannabis are highly lipid soluble and sequestered in brain tissue; thus, our findings are consistent with specific anti-neuroinflammatory effects that may benefit HIV neurologic dysfunction.”

https://pubmed.ncbi.nlm.nih.gov/32554630/

https://nn.neurology.org/content/7/5/e809

Anti-neuroinflammatory effects of grossamide from hemp seed via suppression of TLR-4-mediated NF-κB signaling pathways in lipopolysaccharide-stimulated BV2 microglia cells.

Molecular and Cellular Biochemistry

“Grossamide, a representative lignanamide in hemp seed, has been reported to possess potential anti-inflammatory effects. However, the potential anti-neuroinflammatory effects and underlying mechanisms of action of grossamide are still unclear. Therefore, the present study investigated the possible effects and underlying mechanisms of grossamide against lipopolysaccharide (LPS)-induced inflammatory response in BV2 microglia cells.

This study demonstrated that grossamide significantly inhibited the secretion of pro-inflammatory mediators such as interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), and decreased the level of LPS-mediated IL-6 and TNF-α mRNA. In addition, it significantly reduced the phosphorylation levels of NF-κB subunit p65 in a concentration-dependent manner and suppressed translocation of NF-κB p65 into the nucleus. Furthermore, grossamide markedly attenuated the LPS-induced expression of Toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88).

Taken together, these data suggest that grossamide could be a potential therapeutic candidate for inhibiting neuroinflammation in neurodegenerative diseases.”

https://www.ncbi.nlm.nih.gov/pubmed/28224333

https://link.springer.com/article/10.1007%2Fs11010-016-2923-7